The Effects of Enoximone in Acute Exacerbation COPD
Introduction: The pharmacodynamic properties of enoximone could be beneficial for patients with an Acute Exacerbation COPD (AE-COPD). This research will focus on patients suffering of a severe AE-COPD and the bronchodilatory and inotropic effects of lower doses of enoximone. The main objective of the pilot study is to investigate if there is a bronchodilatory effect of enoximone in patients with AE-COPD. Secondary objective is to investigate a dose responsiveness in a range between 0.5 and 1.5 mg/kg enoximone. Methods: The study design is a prospective interventional non-randomized clinical series study involving patients admitted and intubated at the Intensive Care Unit (ICU) with an AE-COPD. Patients will receive three times a dose of 0.5 mg/kg enoximone with a one-hour-interval. The primary objective is a reduction in auto-positive end-expiratory pressure (PEEP) after enoximone compared to baseline. A dose-titration will test for dose dependency. Secondary objectives are a reduction in ventilator pressures, a reduction in pulmonary artery pressures and an increase in cardiac output.
The effects of enoximone in acute exacerbation COPD: a pilot study
开始日期2020-02-05
申办/合作机构-
100 项与 依诺昔酮 相关的临床结果
登录后查看更多信息
100 项与 依诺昔酮 相关的转化医学
登录后查看更多信息
100 项与 依诺昔酮 相关的专利(医药)
登录后查看更多信息
539
项与 依诺昔酮 相关的文献(医药)
2023-08-01·Intensive care medicine
Retraction Note: Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function.
作者: Herold, Ch ; Knothe, Ch ; Zickmann, B ; Boldt, J ; Dapper, E ; Hempelmann, G
2023-07-01·Intensive care medicine
Retraction Note: The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery - pharmacokinetics and influence on parameters of coagulation.
作者: Boldt, J ; Marck, P ; Dieterich, H A ; Kling, D ; Hempelmann, G
2023-04-01·Chest
Retraction Notice to: "Efficacy of the Phosphodiesterase Inhibitor Enoximone in Complicated Cardiac Surgery" [Chest. 1990;98(1):53-58]